Haemonetics Corporation (HAE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Haemonetics Corporation stock (HAE) is currently trading at $55.93. Haemonetics Corporation PE ratio is 15.61. Haemonetics Corporation PS ratio (Price-to-Sales) is 2.01. Analyst consensus price target for HAE is $87.50. WallStSmart rates HAE as Moderate Buy.
- HAE PE ratio analysis and historical PE chart
- HAE PS ratio (Price-to-Sales) history and trend
- HAE intrinsic value — DCF, Graham Number, EPV models
- HAE stock price prediction 2025 2026 2027 2028 2029 2030
- HAE fair value vs current price
- HAE insider transactions and insider buying
- Is HAE undervalued or overvalued?
- Haemonetics Corporation financial analysis — revenue, earnings, cash flow
- HAE Piotroski F-Score and Altman Z-Score
- HAE analyst price target and Smart Rating
Haemonetics Corporation
📊 No data available
Try selecting a different time range
HAE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Haemonetics Corporation (HAE)
HAE trades at a significant discount to its Graham intrinsic value of $169.88, offering a 66% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Haemonetics Corporation (HAE) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, operating margin, eps growth. Concerns around revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Haemonetics Corporation (HAE) Key Strengths (6)
Growing significantly faster than its price suggests
115.28% of shares held by major funds and institutions
Strong operational efficiency: $21 kept per $100 revenue
Strong earnings growth at 28.40% per year
Mid-cap company balancing growth potential with stability
Solid profitability: $19 profit per $100 equity
Supporting Valuation Data
Haemonetics Corporation (HAE) Areas to Watch (4)
Revenue declining -2.70%, a shrinking business
Revenue is fairly priced at 2.01x sales
Fairly priced relative to book value
Decent profitability, keeps $13 per $100 revenue
Haemonetics Corporation (HAE) Detailed Analysis Report
Overall Assessment
This company scores 67/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.3/10) while 4 fall into concern territory (avg 4.5/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Operating Margin. Valuation metrics including PEG Ratio (0.90) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 19.30%, Operating Margin at 21.00%. Growth metrics are encouraging with EPS Growth at 28.40%.
The Bear Case
The primary concerns are Revenue Growth, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (2.01), Price/Book (2.99) suggest expensive pricing. Growth concerns include Revenue Growth at -2.70%, which may limit upside. Profitability pressure is visible in Profit Margin at 13.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 19.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -2.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Institutional Own.) and negatives (Revenue Growth, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HAE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HAE's Price-to-Sales ratio of 2.01x trades 45% below its historical average of 3.64x (18th percentile). The current valuation is 69% below its historical high of 6.45x set in Dec 2007, and 41% above its historical low of 1.43x in May 2016.
WallStSmart Analysis Synopsis
Data-driven financial summary for Haemonetics Corporation (HAE) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Haemonetics Corporation faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 1.3B with 3% decline year-over-year. Profit margins of 13.3% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 87M in free cash flow and 94M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Haemonetics Corporation push profit margins above 15% as the business scales?
Debt management: total debt of 1.2B is significantly higher than cash (363M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Haemonetics Corporation.
Bottom Line
Haemonetics Corporation faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:40:16 AM
About Haemonetics Corporation(HAE)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.